Literature DB >> 1555345

The early treatment of motion complications after reconstruction of the anterior cruciate ligament.

F R Noyes1, R E Mangine, S D Barber.   

Abstract

The use of active and passive knee motion in the immediate postoperative period and a treatment plan for early postoperative limitations in knee motion has proven highly effective in restoring motion after anterior cruciate ligament (ACL) reconstruction. Of 207 knees, 189 (91%) regained a full range of motion of 0 degrees-135 degrees. The remaining 18 knees (9%) did not regain motion as rapidly as the others and were placed in an early postoperative phased treatment program. Six knees had serial extension casts, nine had early gentle manipulation under anesthesia, and three had arthroscopic lysis of intraarticular adhesions and scar tissue. Fourteen of these 18 knees regained a full range of knee motion. Two of the remaining four knees lacked 5 degrees of full extension, whereas the other two, in patients who had failed to follow medical advice and the rehabilitation program, had permanent and significant limitation of motion. The incidence of postoperative motion problems was related to the extent of the surgical procedure. The incidence was 4% in patients who had only ACL reconstruction, 10% in cases in which added lateral extraarticular procedure had been done, 12% where a meniscus repair had been done, and 23% where a medial collateral ligament repair was done.

Entities:  

Mesh:

Year:  1992        PMID: 1555345

Source DB:  PubMed          Journal:  Clin Orthop Relat Res        ISSN: 0009-921X            Impact factor:   4.176


  15 in total

Review 1.  Failure of Anterior Cruciate Ligament Reconstruction.

Authors:  Gonzalo Samitier; Alejandro I Marcano; Eduard Alentorn-Geli; Ramon Cugat; Kevin W Farmer; Michael W Moser
Journal:  Arch Bone Jt Surg       Date:  2015-10

2.  Arthroscopic posteromedial capsular release for knee flexion contractures.

Authors:  Robert F LaPrade; Andrew C Pedtke; Scott T Roethle
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2008-05       Impact factor: 4.342

3.  Increased Risk of Revision, Reoperation, and Implant Constraint in TKA After Multiligament Knee Surgery.

Authors:  Steven I Pancio; Paul L Sousa; Aaron J Krych; Matthew P Abdel; Bruce A Levy; Diane L Dahm; Michael J Stuart
Journal:  Clin Orthop Relat Res       Date:  2017-01-13       Impact factor: 4.176

4.  Results of surgical treatment of arthrofibrosis after ACL reconstruction.

Authors:  P Aglietti; R Buzzi; R De Felice; G Paolini; G Zaccherotti
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  1995       Impact factor: 4.342

5.  Management of the Patient with an ACL/MCL Injured Knee.

Authors:  Robert E Mangine; Stephen J Minning; Marsha Eifert-Mangine; Angelo J Colosimo; Matthew Donlin
Journal:  N Am J Sports Phys Ther       Date:  2008-11

6.  Outcome of surgical treatment of arthrofibrosis following ligament reconstruction.

Authors:  Sinan Said; Svend Erik Christainsen; Peter Faunoe; Bent Lund; Martin Lind
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2011-03-24       Impact factor: 4.342

7.  Rehabilitation of Patients Following Autogenic Bone-Patellar Tendon-Bone ACL Reconstruction: A 20-Year Perspective.

Authors:  Mark S De Carlo; Ryan McDivitt
Journal:  N Am J Sports Phys Ther       Date:  2006-08

8.  Post-operative problems following anterior cruciate ligament reconstruction.

Authors:  L C Almekinders; T Moore; D Freedman; T N Taft
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  1995       Impact factor: 4.342

9.  POST-OPERATIVE CRITERION BASED REHABILITATION OF ACL REPAIRS: A CLINICAL COMMENTARY.

Authors:  Brett A Bousquet; Luke O'Brien; Steve Singleton; Michael Beggs
Journal:  Int J Sports Phys Ther       Date:  2018-04

Review 10.  Arthrofibrosis Nightmares: Prevention and Management Strategies.

Authors:  Dustin R Lee; Erik Therrien; Bryant M Song; Christopher L Camp; Aaron J Krych; Michael J Stuart; Matthew P Abdel; Bruce A Levy
Journal:  Sports Med Arthrosc Rev       Date:  2022-03-01       Impact factor: 1.985

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.